Investors Buy High Volume of Omeros Call Options (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw unusually large options trading activity on Wednesday. Investors acquired 29,728 call options on the stock. This represents an increase of approximately 579% compared to the average volume of 4,378 call options.

Omeros Price Performance

Shares of OMER traded up $6.88 during mid-day trading on Wednesday, reaching $15.63. 19,775,328 shares of the company’s stock traded hands, compared to its average volume of 1,695,280. Omeros has a 12 month low of $2.95 and a 12 month high of $17.65. The stock has a market cap of $1.11 billion, a P/E ratio of -7.82 and a beta of 2.48. The stock’s 50-day moving average is $8.71 and its two-hundred day moving average is $5.59.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. Research analysts predict that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

A number of large investors have recently modified their holdings of OMER. Vanguard Group Inc. increased its holdings in Omeros by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock worth $26,610,000 after purchasing an additional 95,599 shares during the period. Deutsche Bank AG grew its position in shares of Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 1,973 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Omeros by 169.1% in the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after acquiring an additional 54,696 shares in the last quarter. Nuveen LLC purchased a new stake in Omeros in the first quarter worth about $938,000. Finally, Wellington Management Group LLP bought a new position in Omeros during the 1st quarter worth about $1,118,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: FDA approval of YARTEMLEA — the first and only therapy indicated for transplant‑associated thrombotic microangiopathy (TA‑TMA). This is a clear commercialization catalyst that creates a new, addressable market and removes a major regulatory overhang. Business Wire: FDA Approves YARTEMLEA Reuters: FDA approves Omeros’ drug
• Positive Sentiment: Analyst support — D. Boral Capital reaffirmed a Buy with a $36 price target (~>100% upside from recent levels), and H.C. Wainwright reiterated a Buy with a $20 target; both notes reinforce upside expectations after approval. Benzinga: D. Boral Capital rating TipRanks: H.C. Wainwright note
• Positive Sentiment: Unusual options activity — a large block of ~29,728 call contracts was bought (≈579% above typical call volume), signaling aggressive bullish positioning by traders ahead of or after the approval news. (No direct article link provided in the feed.)
• Neutral Sentiment: Trading halts — OMER was halted twice (early morning “News pending” halt and a later LULD pause). These halts reflect high volatility and are procedural responses to material news and price swings rather than new negative data.
• Neutral Sentiment: Market reaction and liquidity — the stock is trading up on very heavy volume, indicating strong intraday interest; investors should expect elevated volatility as the market digests approval, analyst re-ratings, and positioning flows.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on OMER. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. Finally, Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.67.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.